Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Overcoming barriers to early disease intervention

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Differences in primary prevention, secondary prevention and early disease intervention, depicting target groups, goals and examples for each approach.
Fig. 2: Hypothetical illustrative example of integrated early disease intervention paradigm.

References

  1. Anonymous. Nat. Biotechnol. 37, 197 (2019).

  2. Bluestone, J. A., Herold, K. & Eisenbarth, G. Nature 464, 1293–1300 (2010).

    CAS  Article  Google Scholar 

  3. Diabetes Prevention Trial–Type 1 Diabetes Study Group. N. Engl. J. Med. 346, 1685–1691 (2002).

  4. Egan, M. F. et al. N. Engl. J. Med. 380, 1408–1420 (2019).

    CAS  Article  Google Scholar 

  5. Demongeot, J. et al. Int. J. Mol. Sci. 10, 4437–4473 (2009).

    CAS  Article  Google Scholar 

  6. Foust, K. D. et al. Nat. Biotechnol. 28, 271–274 (2010).

    CAS  Article  Google Scholar 

  7. Groen, E. J. N., Talbot, K. & Gillingwater, T. H. Nat. Rev. Neurol. 14, 214–224 (2018).

    Article  Google Scholar 

  8. Dominguez, E. et al. Hum. Mol. Genet. 20, 681–693 (2011).

    CAS  Article  Google Scholar 

  9. US Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/zolgensma (2019).

  10. Hickey, R. D. et al. Cell Transplant. 28, 79–88 (2019).

    Article  Google Scholar 

  11. Herold, K. C. et al. N. Engl. J. Med. 381, 603–613 (2019).

    CAS  Article  Google Scholar 

  12. Korde, N. et al. JAMA Oncol. 1, 746–754 (2015).

    Article  Google Scholar 

  13. Landgren, O. et al. Leukemia 33, 2127–2143 (2019).

    CAS  Article  Google Scholar 

  14. Zhao, A. L. et al. Cancer Manag. Res. 11, 5599–5611 (2019).

    CAS  Article  Google Scholar 

  15. Pentland, A. Social Physics Vol. 1 (Penguin, 2015).

Download references

Acknowledgements

Our perspective has benefited from a global network of colleagues. In particular, it has been challenged, informed and enriched by conversations with many people, including R. Hendricks, D. Blumenthal, B. Wiegand, K. Wildenhaus, J. Hedrick, S. Brady, G. Pigino, J. M. Peyrin, P. Prieto, J. Fleming and A. Zarur.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H. Hugo Caicedo.

Ethics declarations

Competing interests

D.A.H. consults for Johnson & Johnson, Verily Life Sciences, and Worrell. He has received research support from Olympus. A.P. is on the Advisory Boards of Pear Therapeutics. G.P.P. consults for Johnson & Johnson, Takeda, Bristol-Myers Squibb, Eli Lilly and Tolero, and serves on the Board of Directors of Axcella Health and Celixir.

Additional information

Editorial note: This article has been peer reviewed.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Caicedo, H.H., Hashimoto, D.A., Caicedo, J.C. et al. Overcoming barriers to early disease intervention. Nat Biotechnol 38, 669–673 (2020). https://doi.org/10.1038/s41587-020-0550-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-020-0550-z

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing